Animal study · Supplements / medicine · 3 Oct 2026
Restoring a liver enzyme called UBE2N reduced fat, inflammation, and scarring in a mouse model of fatty liver disease
Source: Cedars-Sinai / Nature Metabolism
What the research found
Study (mice; preclinical). Ekihiro Seki and colleagues, including Cedars-Sinai, report in Nature Metabolism (2026; 8(9):1926; doi 10.1038/s42255-026-01590-0; ScienceDaily 3 October 2026). The American Liver Foundation figure quoted in the release is that about 100 million people in the United States have metabolic dysfunction-associated steatotic liver disease, and that roughly 20% to 25% of them develop the inflammatory, scarring form called MASH. The group found that the enzyme UBE2N falls in liver cells as that disease advances. UBE2N helps clear damaged mitochondria and break down fat. Restoring it in laboratory mice reduced fat accumulation, inflammation, and scarring. There is no cure for MASH; current care is mainly lifestyle change, and medicines remain limited. This is a mouse result, not a human treatment trial. Educational notes. This is not a supplement for fatty liver.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34